The operating activities of the Merck Group are organized into four divisions. The Merck Serono division develops, manufactures and markets prescription drugs to treat neurodegenerative diseases, cancer, infertility, cardiovascular diseases and selected metabolic disorders. More than 60% of Merck Serono’s sales are generated with biologics, making the division one of Europe’s leading suppliers of biopharmaceuticals. In the third quarter of 2013, Merck Serono accounted for around 56% of Group sales.
The Consumer Health division manufactures and markets over-the-counter pharmaceuticals that primarily address health themes such as mobility, women’s and children’s health, cough and cold as well as everyday health protection. This division’s contribution to Group sales was around 5% in the third quarter of 2013.
With its Performance Materials division, Merck is the market leader in liquid crystal mixtures for liquid crystal displays (LCDs) as well as in special effect pigments for decorative applications, e.g. in automotive coatings and the cosmetics industry. The division generated around 15% of Group sales in the third quarter of 2013.
The Merck Millipore division is one of the top three suppliers of products and services within its relevant market segments for the life science industry, developing and marketing solutions to support the academic, pharmaceutical, biopharmaceutical and chemical industries to increase productivity in laboratories as well as to ensure quality, increase yields and lower costs in pharmaceutical production. Reflecting the industry-specific needs of its customers, Merck Millipore has three business units: Bioscience and Lab Solutions, which both primarily serve the needs of researchers and laboratories, and Process Solutions, which supplies products used primarily for pharmaceutical production. In the third quarter of 2013, the division generated around 24% of Group sales.
Merck Group | Sales by division – Q3 2013
| XLS |
|
Merck Group | EBITDA pre one-time items by division | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ million |
Q3 – 2013 |
Q3 – 2012 |
Change |
Jan.–Sept. |
Jan.–Sept. |
Change |
|
Merck Serono |
501.4 |
465.7 |
7.7% |
1,455.1 |
1,318.4 |
10.4% |
|
Consumer Health |
24.2 |
19.3 |
25.4% |
57.8 |
47.2 |
22.4% |
|
Performance Materials |
196.8 |
197.3 |
–0.2% |
613.2 |
553.5 |
10.8% |
|
Merck Millipore |
157.2 |
152.0 |
3.4% |
475.0 |
470.9 |
0.9% |
|
Corporate and Other |
–48.9 |
–80.1 |
–38.9 |
–142.9 |
–214.9 |
–33.5% |
|
Merck Group |
830.7 |
754.2 |
10.1% |
2,458.1 |
2,175.1 |
13.0% |